IP Library Granted Patent US 12685755
Granted Patent B2
US 12685755 · App. 18/615,134 · Granted Jul 21, 2026

Methods and compositions for treating mucosal tissue disorders

Inventors: Roland R. Arnold (Chapel Hill, NC); David C. Henke (Chapel Hill, NC)
Assignee: The University of North Carolina at Chapel Hill
A61K38/063A01N1/126A61K9/0031A61K9/0034A61K9/006A61K9/0073A61K9/0075A61K9/008A61K31/198A61K31/375A61K33/00A61K33/04A61K33/10A61K38/40A61K38/443A61K45/06C12Y101/03004C12Y111/01007C12Y302/01011C12Y302/01017C12Y302/01059
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12685755
App. No.
18/615,134
Granted
Jul 21, 2026
Kind
B2
Abstract

The present invention provides compositions and formulations comprising glutathione with or without thiocyanate and methods of use thereof to treat diseases and disorders in mucosal/epithelial tissue.

Claims (18)

1 . A method for treating a pulmonary or airway disorder or disease in an airway of a subject in need thereof, comprising administering to the airway of the subject by inhalation an effective amount of a composition comprising:

a) a glutathione, or a pharmaceutically-acceptable salt of glutathione;

b) an organic acid or a pharmaceutically-acceptable salt of an organic acid; and

c) a carrier,

wherein the composition has a pH from about 5 to about 9, and

wherein the pulmonary or airway disorder or disease is selected from the group consisting of chronic inflammatory lung disease, inflammation associated with lung transplantation, acute lung rejection, asthma, cystic fibrosis, chronic obstructive pulmonary disease (COPD), and any combination thereof.

2 . The method of claim 1 , wherein the organic acid is ascorbic acid.

3 . The method of claim 1 , wherein the carrier is water.

4 . The method of claim 1 , wherein the composition further comprises a bicarbonate salt.

5 . The method of claim 4 , wherein the bicarbonate salt is sodium bicarbonate or potassium bicarbonate.

6 . The method of claim 1 , wherein the composition comprises: a glutathione, or a pharmaceutically-acceptable salt of glutathione; ascorbic acid; sodium bicarbonate, and a carrier.

7 . The method of claim 1 , wherein the composition is in the form of a particle.

8 . The method of claim 7 , wherein the particle is mixed with a gas or liquid propellant for use in inhalation therapy.

9 . The method of claim 1 , further comprising administering to the subject an effective amount of an inhaled corticosteroid (ICS) or bronchodilator.

10 . The method of claim 1 , further comprising a step of administering to the subject an effective amount of Fluticasone, Budesonide, Mometasone, Ciclesonide, Flunisolide, Beclomethasone, Albuterol, Levalbuterol, Ipratropium, Tiotropium, Formoterol, Arformoterol, Indacaterol, Aclidinium, Pirbuterol, or any combination thereof.

11 . The method of claim 1 , wherein the glutathione is oxidized glutathione.

12 . The method of claim 1 , wherein the glutathione is reduced glutathione.

13 . The method of claim 1 , wherein upon administration of the composition to the subject, the concentration of glutathione in airway surface liquid of the subject is from about 0.1 mM to about 1.0 mM.